A Phase 3 interventional study of Meningococcal vaccine GSK134612 and Infanrix™ hexa in Infections, Meningococcal, sponsored by GlaxoSmithKline. Completed at 89 sites in 3 countries. Open to participants aged 12 Months to 23 Months, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-01-24.
Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 71 studies in Meningococcal Infections by GlaxoSmithKline — none open to participants now, 1 under way, none of them phase 3. Meningococcal Infections · GlaxoSmithKline.
Among the 71 studies in Meningococcal Infections by GlaxoSmithKline, this one is the 24th largest by enrollment of the 67 interventional ones that give a count, is one of 12 that started in 2007, is one of 34 in phase 3, and was the 26th registered.
243 studies on the registry are indexed under Meningococcal Infections; 8 are open to participants now.
Browse Meningococcal Infections studies →None of the 71 studies in Meningococcal Infections by GlaxoSmithKline is open now. The open studies under Meningococcal Infections, anywhere →
Of the 7 Meningococcal Infections studies recruiting now, 3 set no upper age limit and 4 stop at 75 or younger; 4 take children under 18; 6 take healthy volunteers.
This study: 12 Months to 23 Months · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
71 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 26 · Phase 3 34 · Phase 4 6
First in 2002; this study’s year is marked. 12 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 793 is above the median of 456 across 214 interventional studies indexed under Meningococcal Infections.
Median enrollment 613 across the 67 interventional studies, 119 across the 4 observational. Of the 70 that completed or were terminated, 60 (86%) have results posted.
This tab as a report to print or save as PDF → With an account.
GlaxoSmithKline is the lead sponsor of 3,652 studies on the registry; 118 are open to participants now.
Of its 267 completed or terminated interventional studies of FDA-regulated products, 241 (90%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 71 studies in Meningococcal Infections by GlaxoSmithKline, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to demonstrate, in 12-23 months old subjects, the non-inferiority of meningococcal vaccine GSK134612 co-administered with Infanrix hexa™, compared to each vaccine administered individually and to licensed meningococcal vaccine Meningitec™.
The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.
Multicentre study with 4 parallel groups. One group will receive GSK134612 co-administered with Infanrix hexa™, two groups will receive sequential administration of GSK134612 and Infanrix hexa™ and the final group will receive Meningitec™.
For subjects in Groups B and C, three blood samples will be taken: prior to first vaccination and 1 month after each vaccination.
For subjects in Groups A and D, two blood samples will be taken: prior to and 1 month after vaccination.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Additional criteria for subjects receiving Infanrix hexa™
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Meningococcal vaccine GSK134612 co-administered with Infanrix hexa™
Biological: Meningococcal vaccine GSK134612 · Biological: Infanrix™ hexa
Meningococcal vaccine GSK134612 followed one month later by Infanrix hexa™
Biological: Meningococcal vaccine GSK134612 · Biological: Infanrix™ hexa
Infanrix hexa™ followed one month later by Meningococcal vaccine GSK134612
Biological: Meningococcal vaccine GSK134612 · Biological: Infanrix™ hexa
Meningitec™ vaccination
Biological: Meningitec™
Single dose intramuscular injection
Single dose intramuscular injection
Single dose intramuscular injection
Number of Subjects With rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-MenY Titers ≥ the Cut-off.
The cut-off for the assay was greater than or equal to (≥) 1:8. The analysis was based only on subjects receiving Nimenrix vaccination at Day 0.
Time frame: 1 month after vaccination with Nimenrix vaccine (Month 1)
Anti-PT, Anti-FHA and Anti-PRN Concentrations
The analysis was based only on subjects receiving Infanrix-hexa vaccination. The results were calculated as geometric mean expressed in enzyme-linked immunosorbent assay (ELISA) units per milliliter (EL.U/mL).
Time frame: 1 month after the first vaccination (Month 1)
Number of Subjects With Anti-HBs Concentrations ≥ the Cut-off
The cut-off for the assay was greater than or equal to (≥) 10 milli-interantional units per milliliter (mIU/mL).
Time frame: 1 month after vaccination with Nimenrix vaccine (Month 1)
Number of Subjects With Anti-PRP Concentrations ≥ the Cut-off
The cut-off for the assay was ≥ 1μg/mL.
Time frame: 1 month after vaccination with Nimenrix vaccine (Month 1)
Number of Subjects With rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-MenY Titers ≥ the Cut-off Values
The cut-off values for the assay were ≥ 1:8 and ≥ 1:128
Time frame: At month 0, month 1 and month 2
rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-MenY Titers
The results were tabulated as geometric mean expressed in titers.
Time frame: At month 0, month 1 and month 2
Number of Subjects With Anti-polysaccharide A (Anti-PSA), Anti-PSC, Anti-PSW, and Anti-PSY ≥ the Cut-off
The cut-off for the assay were ≥ 0.3 microgram per milliliter (μg/mL) and ≥ 2.0 μg/mL, respectively.
Time frame: At month 0, month 1 and month 2
Anti-polysaccharide A (Anti-PSA), Anti-PSC, Anti-PSW, and Anti-PSY Antibody Concentrations
The results for the assay were tabulated as geometric mean expressed in microgram per milliliter (μg/mL).
Time frame: At month 0, month 1 and month 2
Number of Seroprotected Subjects for Anti-tetanus Toxoid (Anti-TT)
The cut-off for the assay was ≥ 0.1
Time frame: At month 0, month 1 and month 2
Anti-tetanus Toxoid (Anti-TT) Antibody Concentrations
The results for the assay were tabulated as geometric mean expressed in internationl units per milliliter (IU/mL).
Time frame: At month 0, month 1 and month 2
Number of Subjects Seroprotected for Anti-diphtheria (Anti-D) ≥ the Cut-off
The cut-off for the assay was ≥ 0.1
Time frame: At month 0, month 1 and month 2
Anti-diphtheria (Anti-D) Antibody Concentrations
The results for the assay were tabulated as geometric mean expressed in internationl units per milliliter (IU/mL).
Time frame: At month 0, month 1 and month 2
Number of Subjects Seroprotected for Anti-polio Type 1, 2 & 3 ≥ the Cut-off
The cut-off for the assay was ≥ 1:8.
Time frame: At month 0, month 1 and month 2
Anti-polio Type 1, 2 & 3 Titers
The results for the assay were tabulated as geometric mean expressed in titers.
Time frame: At month 0, 1 and 2
Numbers of Seroprotected Subjects for Anti-PRP ≥ the Cut-off
The cut-off for the assay was ≥ 1.0
Time frame: At month 0, month 1 and month 2
Anti-PRP Antibody Concentrations
The results for the assay were tabulated as geometric mean expressed in microgram per milliliter (μg/mL).
Time frame: At month 0, month 1 and month 2
Number of Seroprotected Subjects for Anti-HBs ≥ the Cut-offs
The cut-offs for the assay were ≥ 10 mIU/mL and ≥ 100 mIU/mL respectively .
Time frame: At month 0, month 1 and month 2
Anti-HBs Antibody Concentrations
The results for the assay were tabulated as geometric mean expressed in milli-international units per milliliter (mIU/mL).
Time frame: At month 0, month 1 and month 2
Number of Subjects With a Vaccine Response to PT, FHA and PRN Antigens
Vaccine response to these antigens is defined as appearance of antibodies in subjects who were seronegative (antibody concentration \< 5 EL.U/mL) at pre-vaccination or as at least a 2-fold increase in post-over pre-vaccination antibody concentrations in subjects seropositive at pre-vaccination. The analysis was based only on subjects receiving experimental vaccination.
Time frame: 1 month after vaccination (Month 1)
Anti-PT, Anti-FHA and Anti-PRN Antibody Concentrations
The results were tabulated as geometric mean expressed in enzyme-linked immunosorbent assay (ELISA) units per milliliter (EL.U/mL).
Time frame: At month 0, month 1 and month 2
Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms Post-meningococcal Vaccination
Solicited local symptoms assessed were pain, redness and swelling. Any was defined as occurrence of any local symptom irrespective of intensity grade. Grade 3 Pain was defined as crying when limb was moved/ spontaneously painful.
Time frame: During the 4-day (Days 0-3) follow-up period after Nimenrix or Meningitec vaccination
Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms Post-combined Diphtheria Vaccination
The analysis was based only on subjects receiving combined-diphtheria vaccination.
Time frame: During the 4-day (Days 0-3) follow-up period after Infanrix-hexa vaccination
Number of Subjects Reporting Any Solicited General Symptoms Following Each Dose
Solicited general symptoms assessed were drowsiness, fever, irritability and loss of appetite. Any was defined as occurrence of any general symptom irrespective of intensity grade and relationship. Subjects in the Nimenrix + Infanrix-hexa Group did not receive a second dose of vaccination.
Time frame: During the 4-day (Days 0-3) post-vaccination dose 1 (D1) and second dose (D2)
Number of Subjects Reporting Any Rash
Any was defined as occurrence of at least one symptom experienced.
Time frame: Day 0 - Month 7
Number of Subjects Reporting Any New Onset of Chronic Illnesses (NOCIs)
Any was defined as occurrence of at least one symptom experienced.
Time frame: Day 0 - Month 7
Number of Subjects Reporting Any Conditions Prompting Emergency Room Visits (ER)
Any was defined as occurrence of at least one symptom experienced.
Time frame: Day 0 - Month 7
Number of Subjects Reporting Any Unsolicited Adverse Events (AEs) After the First Dose
An AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. "Any" was defined as an incidence of an unsolicited AE regardless of intensity or relationship to study vaccination.
Time frame: Occurring within Day 0-30 following vaccination
Number of Subjects Reporting Any Unsolicited Adverse Events (AEs) After the Second Dose
An AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. "Any" was defined as an incidence of an unsolicited AE regardless of intensity or relationship to study vaccination. The analysis was based only on subjects receiving a second dose of vaccination.
Time frame: Occurring within Day 0-30 following vaccination
Number of Subjects Reporting Any Serious Adverse Events (SAEs)
Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/ incapacity.
Time frame: From dose 1 (Month 0) up to study end (Month 7)
| Milestone | Nimenrix + Infanrix-hexa Group | Nimenrix Group | Infanrix-Hexa Group | Meningitec Group |
|---|---|---|---|---|
| Started | 222 | 220 | 224 | 127 |
| Completed | 219 | 212 | 218 | 126 |
| Not completed | 3 | 8 | 6 | 1 |
| Withdrew: Other | 0 | 1 | 1 | 0 |
| Withdrew: Serious adverse event | 0 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 3 | 4 | 4 | 0 |
| Withdrew: Migrated/ moved from study area | 0 | 1 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 1 | 1 | 1 |
The cut-off for the assay was greater than or equal to (≥) 1:8. The analysis was based only on subjects receiving Nimenrix vaccination at Day 0.
| Participants | Nimenrix + Infanrix-hexa Group | Nimenrix Group |
|---|---|---|
| rSBA-MenA, M1 | 193 | 180 |
| rSBA-MenC, M1 | 191 | 178 |
| rSBA-MenW-135, M1 | 193 | 183 |
| rSBA-MenY, M1 | 192 | 180 |
The analysis was based only on subjects receiving Infanrix-hexa vaccination. The results were calculated as geometric mean expressed in enzyme-linked immunosorbent assay (ELISA) units per milliliter (EL.U/mL).
| EL.U/mL | Nimenrix + Infanrix-hexa Group | Infanrix-Hexa Group |
|---|---|---|
| Anti-PT, M1 | 86 (77 to 95) | 85 (75 to 96) |
| Anti-FHA, M1 | 542 (492 to 597) | 544 (485 to 611) |
| Anti-PRN, M1 | 470 (411 to 537) | 450 (387 to 522) |
The cut-off for the assay was greater than or equal to (≥) 10 milli-interantional units per milliliter (mIU/mL).
| Participants | Nimenrix + Infanrix-hexa Group | Infanrix-Hexa Group |
|---|---|---|
| Number of Subjects With Anti-HBs Concentrations ≥ the Cut-off | 180 | 166 |
The cut-off for the assay was ≥ 1μg/mL.
| Participants | Nimenrix + Infanrix-hexa Group | Infanrix-Hexa Group |
|---|---|---|
| Number of Subjects With Anti-PRP Concentrations ≥ the Cut-off | 183 | 170 |
The cut-off values for the assay were ≥ 1:8 and ≥ 1:128
| Participants | Nimenrix + Infanrix-hexa Group | Nimenrix Group | Infanrix-Hexa Group | Meningitec Group |
|---|---|---|---|---|
| rSBA-MenA [M 0], ≥1:8 | 30 | 32 | 34 | 18 |
| rSBA-MenA [M 1], ≥1:8 | 193 | 180 | 71 | 43 |
| rSBA-MenA [M 2], ≥1:8 | — | 90 | 178 | — |
| rSBA-MenA [M 0], ≥1:128 | 18 | 21 | 24 | 11 |
| rSBA-MenA [M 1], ≥1:128 | 193 | 179 | 57 | 30 |
| rSBA-MenA [M 2], ≥1:128 | — | 90 | 178 | — |
| rSBA-MenC [M 0], ≥1:8 | 20 | 25 | 13 | 11 |
| rSBA-MenC [M 1], ≥1:8 | 191 | 178 | 34 | 112 |
| rSBA-MenC [M 2], ≥1:8 | — | 91 | 178 | — |
| rSBA-MenC [M 0], ≥1:128 | 5 | 8 | 5 | 3 |
| rSBA-MenC [M 1], ≥1:128 | 189 | 172 | 14 | 102 |
| rSBA-MenC [M 2], ≥1:128 | — | 85 | 157 | — |
| rSBA-MenW-135 [M 0], ≥1:8 | 43 | 42 | 46 | 22 |
| rSBA-MenW-135 [M 1], ≥1:8 | 193 | 183 | 86 | 41 |
| rSBA-MenW-135 [M 2], ≥1:8 | — | 91 | 179 | — |
| rSBA-MenW-135 [M 0], ≥1:128 | 17 | 11 | 23 | 10 |
| rSBA-MenW-135 [M 1] ≥1:128 | 193 | 180 | 49 | 23 |
| rSBA-MenW-135 [M 2], ≥1:128 | — | 90 | 178 | — |
| rSBA-MenY [M 0], ≥1:8 | 57 | 53 | 53 | 30 |
| rSBA-MenY [M 1], ≥1:8 | 192 | 180 | 103 | 71 |
| rSBA-MenY [M 2], ≥1:8 | — | 91 | 178 | — |
| rSBA-MenY [M 0], ≥1:128 | 38 | 37 | 34 | 20 |
| rSBA-MenY [M 1], ≥1:128 | 192 | 178 | 79 | 38 |
| rSBA-MenY [M 2], ≥1:128 | — | 91 | 178 | — |
The results were tabulated as geometric mean expressed in titers.
| Titers | Nimenrix + Infanrix-hexa Group | Nimenrix Group | Infanrix-Hexa Group | Meningitec Group |
|---|---|---|---|---|
| rSBA-MenA [M 0] | 15 (10 to 22.4) | 19 (12.2 to 29.5) | 24 (15 to 38.4) | 15.9 (9.2 to 27.5) |
| rSBA-MenA [M 1] | 3152.9 (2752.5 to 3611.4) | 3169.9 (2577.2 to 3898.8) | 24.2 (17.4 to 33.7) | 21.5 (14.5 to 32.1) |
| rSBA-MenA [M 2] | — | 2881.9 (2292 to 3623.6) | 1938.3 (1699.1 to 2211.2) | — |
| rSBA-MenC [M 0] | 7.4 (5.7 to 9.6) | 9.1 (6.7 to 12.2) | 6.1 (4.9 to 7.7) | 7.6 (5.2 to 11.2) |
| rSBA-MenC [M 1] | 879.7 (763.1 to 1014) | 828.7 (672.4 to 1021.4) | 7.5 (6.1 to 9.3) | 691.4 (520.8 to 917.9) |
| rSBA-MenC [M 2] | — | 519.6 (391.7 to 689.2) | 386 (333.9 to 446.2) | — |
| rSBA-MenW-135 [M 0] | 19 (13.1 to 27.6) | 19.2 (13.3 to 27.7) | 24.8 (16.7 to 36.8) | 15.6 (9.8 to 25) |
| rSBA-MenW-135 [M 1] | 4147 (3670.1 to 4685.8) | 4022.3 (3269.2 to 4948.8) | 25.2 (18.6 to 34.2) | 14.2 (10.2 to 19.7) |
| rSBA-MenW-135 [M 2] | — | 3630.1 (2899.1 to 4545.4) | 2466.4 (2175.4 to 2796.4) | — |
| rSBA-MenY [M 0] | 36.8 (24.7 to 54.8) | 45.4 (29.1 to 71) | 41.2 (26.7 to 63.4) | 32 (18.3 to 55.9) |
| rSBA-MenY [M 1] | 3461.8 (2990.1 to 4007.9) | 3167.7 (2521.9 to 3978.9) | 45.9 (33 to 63.9) | 47.2 (32.1 to 69.3) |
| rSBA-MenY [M 2] | — | 3010.4 (2325.3 to 3897.3) | 2446.9 (2088.5 to 2866.8) | — |
The cut-off for the assay were ≥ 0.3 microgram per milliliter (μg/mL) and ≥ 2.0 μg/mL, respectively.
| Participants | Nimenrix + Infanrix-hexa Group | Nimenrix Group | Infanrix-Hexa Group | Meningitec Group |
|---|---|---|---|---|
| Anti-PSA [Month 0], ≥0.3 | 4 | 1 | 1 | 1 |
| Anti-PSA [Month 1], ≥0.3 | 46 | 45 | 1 | 1 |
| Anti-PSA [Month 2], ≥0.3 | — | 44 | 42 | — |
| Anti-PSA [Month 0], ≥2.0 | 0 | 0 | 0 | 0 |
| Anti-PSA [Month 1], ≥2.0 | 46 | 44 | 1 | 0 |
| Anti-PSA [Month 2], ≥2.0 | 0 | 43 | 40 | 0 |
| Anti-PSC [Month 0], ≥0.3 | 1 | 1 | 2 | 0 |
| Anti-PSC [Month 1], ≥0.3 | 51 | 41 | 2 | 28 |
| Anti-PSC [Month 2], ≥0.3 | — | 41 | 47 | — |
| Anti-PSC [Month 0], ≥2.0 | 1 | 0 | 0 | 0 |
| Anti-PSC [Month 1], ≥2.0 | 50 | 41 | 0 | 26 |
| Anti-PSC [Month 2], ≥2.0 | — | 41 | 43 | — |
| Anti-PSW-135 [Month 0], ≥0.3 | 1 | 1 | 2 | 0 |
| Anti-PSW-135 [Month 1], ≥0.3 | 44 | 43 | 2 | 0 |
| Anti-PSW-135 [Month 2], ≥0.3 | 0 | 43 | 41 | 0 |
| Anti-PSW-135 [Month 0], ≥2.0 | 0 | 0 | 1 | 0 |
| Anti-PSW-135 [Month 1], ≥2.0 | 40 | 39 | 2 | 0 |
| Anti-PSW-135 [Month 2], ≥2.0 | — | 36 | 29 | — |
| Anti-PSY [Month 0], ≥0.3 | 1 | 1 | 0 | 0 |
| Anti-PSY [Month 1], ≥0.3 | 45 | 43 | 1 | 0 |
| Anti-PSY [Month 2], ≥0.3 | — | 44 | 41 | — |
| Anti-PSY [Month 0], ≥2.0 | 0 | 0 | 0 | 0 |
| Anti-PSY [Month 1], ≥2.0 | 40 | 42 | 1 | 0 |
| Anti-PSY [Month 2], ≥2.0 | — | 40 | 34 | — |
The results for the assay were tabulated as geometric mean expressed in microgram per milliliter (μg/mL).
| μg/mL | Nimenrix + Infanrix-hexa Group | Nimenrix Group | Infanrix-Hexa Group | Meningitec Group |
|---|---|---|---|---|
| Anti-PSA [M 0] | 0.17 (0.15 to 0.19) | 0.15 (0.15 to 0.16) | 0.16 (0.14 to 0.18) | 0.16 (0.14 to 0.18) |
| Anti-PSA [M 1] | 31.01 (23.73 to 40.52) | 33.15 (21.89 to 50.18) | 0.17 (0.13 to 0.22) | 0.16 (0.14 to 0.18) |
| Anti-PSA [M 2] | — | 16.93 (12.39 to 23.13) | 12.28 (9.38 to 16.06) | — |
| Anti-PSC [M 0] | 0.16 (0.14 to 0.2) | 0.16 (0.14 to 0.17) | 0.16 (0.15 to 0.17) | 0.15 (0.15 to 0.15) |
| Anti-PSC [M 1] | 13.74 (10.68 to 17.67) | 23.52 (18.91 to 29.25) | 0.16 (0.15 to 0.17) | 7.99 (5.57 to 11.46) |
| Anti-PSC [M 2] | — | 9.73 (7.82 to 12.12) | 5.84 (4.66 to 7.32) | — |
| Anti-PSW-135 [M 0] | 0.16 (0.14 to 0.17) | 0.15 (0.15 to 0.16) | 0.17 (0.14 to 0.22) | 0.15 (0.15 to 0.15) |
| Anti-PSW-135 [M 1] | 6.43 (4.92 to 8.4) | 4.15 (2.82 to 6.11) | 0.18 (0.14 to 0.22) | 0.15 (0.15 to 0.15) |
| Anti-PSW-135 [M 2] | — | 3.99 (2.91 to 5.48) | 3.4 (2.52 to 4.59) | — |
| Anti-PSY [M 0] | 0.15 (0.15 to 0.16) | 0.15 (0.15 to 0.16) | 0.15 (0.15 to 0.15) | 0.15 (0.15 to 0.15) |
| Anti-PSY [M 1] | 6.52 (4.91 to 8.65) | 9.42 (6.49 to 13.66) | 0.17 (0.13 to 0.21) | 0.15 (0.15 to 0.15) |
| Anti-PSY [M 2] | — | 7.86 (6.04 to 10.23) | 4.76 (3.73 to 6.09) | — |
The cut-off for the assay was ≥ 0.1
| Participants | Nimenrix + Infanrix-hexa Group | Nimenrix Group | Infanrix-Hexa Group | Meningitec Group |
|---|---|---|---|---|
| anti-TT [M 0], ≥0.1 | 177 | 161 | 155 | 99 |
| anti-TT [M 1], ≥0.1 | 184 | 177 | 173 | 99 |
| anti-TT [M 2], ≥0.1 | — | 177 | 176 | — |
The results for the assay were tabulated as geometric mean expressed in internationl units per milliliter (IU/mL).
| IU/mL | Nimenrix + Infanrix-hexa Group | Nimenrix Group | Infanrix-Hexa Group | Meningitec Group |
|---|---|---|---|---|
| anti-TT [M 0] | 0.481 (0.417 to 0.554) | 0.39 (0.332 to 0.457) | 0.416 (0.354 to 0.489) | 0.393 (0.325 to 0.475) |
| anti-TT [M 1] | 10.47 (9.131 to 12.007) | 7.941 (6.517 to 9.677) | 6.189 (5.404 to 7.089) | 0.374 (0.306 to 0.457) |
| anti-TT [M 2] | — | 13.966 (12.199 to 15.987) | 8.236 (7.348 to 9.231) | — |
The cut-off for the assay was ≥ 0.1
| Participants | Nimenrix + Infanrix-hexa Group | Nimenrix Group | Infanrix-Hexa Group | Meningitec Group |
|---|---|---|---|---|
| anti-D [M 0], ≥0.1 | 169 | 157 | 154 | 94 |
| anti-D [M 1], ≥0.1 | 184 | 156 | 173 | 109 |
| anti-D [M 2], ≥0.1 | — | 176 | 176 | — |
The results for the assay were tabulated as geometric mean expressed in internationl units per milliliter (IU/mL).
| IU/mL | Nimenrix + Infanrix-hexa Group | Nimenrix Group | Infanrix-Hexa Group | Meningitec Group |
|---|---|---|---|---|
| anti-D [M 0] | 0.477 (0.407 to 0.559) | 0.476 (0.397 to 0.57) | 0.437 (0.367 to 0.521) | 0.452 (0.355 to 0.574) |
| anti-D [M 1] | 7.636 (6.889 to 8.465) | 0.404 (0.335 to 0.487) | 7.292 (6.362 to 8.358) | 5.201 (4.243 to 6.376) |
| anti-D [M 2] | — | 8.561 (7.553 to 9.703) | 5.21 (4.623 to 5.872) | — |
The cut-off for the assay was ≥ 1:8.
| Participants | Nimenrix + Infanrix-hexa Group | Nimenrix Group | Infanrix-Hexa Group | Meningitec Group |
|---|---|---|---|---|
| anti-p1 [M 0] | 158 | 143 | 142 | 90 |
| anti-p1 [M 1] | 166 | 149 | 163 | 89 |
| anti-p1 [M 2] | — | 159 | 161 | — |
| anti-p2 [M 0] | 153 | 141 | 145 | 80 |
| anti-p2 [M 1] | 166 | 147 | 161 | 80 |
| anti-p2 [M 2] | — | 159 | 161 | — |
| anti-p3 [M 0] | 155 | 148 | 143 | 88 |
| anti-p3 [M 1] | 167 | 150 | 160 | 87 |
| anti-p3 [M 2] | — | 159 | 159 | — |
The results for the assay were tabulated as geometric mean expressed in titers.
| Titers | Nimenrix + Infanrix-hexa Group | Nimenrix Group | Infanrix-Hexa Group | Meningitec Group |
|---|---|---|---|---|
| anti-p1 [M 0] | 84.2 (67.2 to 105.4) | 72.5 (55.6 to 94.5) | 83.6 (65.5 to 106.6) | 71.7 (51.7 to 99.6) |
| anti-p1 [M 1] | 984.4 (830.4 to 1167) | 74.2 (56.7 to 97.3) | 1308.5 (1073.2 to 1595.5) | 66.3 (46.6 to 94.4) |
| anti-p1 [M 2] | — | 1288.2 (1052.5 to 1576.6) | 1108.4 (913.5 to 1344.8) | — |
| anti-p2 [M 0] | 76.8 (60.8 to 97) | 66.3 (50.9 to 86.5) | 65.6 (51.2 to 84.2) | 49.3 (34.9 to 69.6) |
| anti-p2 [M 1] | 1372 (1153.5 to 1631.9) | 70.3 (53.4 to 92.6) | 1540.4 (1253.2 to 1893.2) | 49.8 (34.5 to 71.9) |
| anti-p2 [M 2] | — | 1650.5 (1358.5 to 2005.3) | 1174.5 (961.4 to 1434.8) | — |
| anti-p3 [M 0] | 104.4 (81.1 to 134.4) | 99.8 (77.5 to 128.5) | 113.2 (86.9 to 147.5) | 102.9 (72.8 to 145.4) |
| anti-p3 [M 1] | 2295.6 (1952.1 to 2699.4) | 96.6 (74.2 to 125.8) | 2034.3 (1594.9 to 2594.8) | 85.3 (58.7 to 124.1) |
| anti-p3 [M 2] | — | 2478 (2049.2 to 2996.4) | 1655.1 (1308.9 to 2092.9) | — |
The cut-off for the assay was ≥ 1.0
| Participants | Nimenrix + Infanrix-hexa Group | Nimenrix Group | Infanrix-Hexa Group | Meningitec Group |
|---|---|---|---|---|
| anti-PRP [M 0] ≥1.0 | 73 | 64 | 65 | 34 |
| anti-PRP [M 1] ≥1.0 | 183 | 70 | 170 | 34 |
| anti-PRP [M 2] ≥1.0 | — | 172 | 170 | — |
The results for the assay were tabulated as geometric mean expressed in microgram per milliliter (μg/mL).
| μg/mL | Nimenrix + Infanrix-hexa Group | Nimenrix Group | Infanrix-Hexa Group | Meningitec Group |
|---|---|---|---|---|
| anti-PRP [M 0] | 0.806 (0.658 to 0.987) | 0.665 (0.528 to 0.839) | 0.766 (0.596 to 0.986) | 0.585 (0.449 to 0.762) |
| anti-PRP [M 1] | 25.556 (21.358 to 30.579) | 0.711 (0.56 to 0.904) | 31.165 (25.142 to 38.631) | 0.55 (0.42 to 0.72) |
| anti-PRP [M 2] | — | 12.239 (10.392 to 14.414) | 21.023 (17.036 to 25.942) | — |
The cut-offs for the assay were ≥ 10 mIU/mL and ≥ 100 mIU/mL respectively .
| Participants | Nimenrix + Infanrix-hexa Group | Nimenrix Group | Infanrix-Hexa Group | Meningitec Group |
|---|---|---|---|---|
| anti-HBS [M 0] ≥10 | 173 | 158 | 155 | 95 |
| anti-HBS [M 1] ≥10 | 180 | 160 | 166 | 100 |
| anti-HBS [M 2] ≥10 | — | 172 | 167 | — |
| anti-HBS [M 0] ≥100 | 92 | 80 | 75 | 46 |
| anti-HBS [M 1] ≥100 | 169 | 85 | 155 | 46 |
| anti-HBS [M 2] ≥100 | — | 168 | 158 | — |
The results for the assay were tabulated as geometric mean expressed in milli-international units per milliliter (mIU/mL).
| mIU/mL | Nimenrix + Infanrix-hexa Group | Nimenrix Group | Infanrix-Hexa Group | Meningitec Group |
|---|---|---|---|---|
| anti-HBS [M 0] | 111.6 (90.9 to 136.9) | 92.8 (75.3 to 114.4) | 101.2 (81.5 to 125.7) | 85.6 (65.7 to 111.5) |
| anti-HBS [M 1] | 2048.4 (1589.3 to 2640) | 95 (74.8 to 120.6) | 1711.6 (1292.7 to 2266.3) | 101.6 (75.5 to 136.7) |
| anti-HBS [M 2] | — | 2392.3 (1841.7 to 3107.4) | 1241 (976.2 to 1577.7) | — |
Vaccine response to these antigens is defined as appearance of antibodies in subjects who were seronegative (antibody concentration \< 5 EL.U/mL) at pre-vaccination or as at least a 2-fold increase in post-over pre-vaccination antibody concentrations in subjects seropositive at pre-vaccination. The analysis was based only on subjects receiving experimental vaccination.
| Participants | Nimenrix + Infanrix-hexa Group | Nimenrix Group | Infanrix-Hexa Group |
|---|---|---|---|
| Anti-PT | 180 | 169 | 163 |
| Anti-FHA | 184 | 159 | 158 |
| Anti-PRN | 186 | 173 | 172 |
The results were tabulated as geometric mean expressed in enzyme-linked immunosorbent assay (ELISA) units per milliliter (EL.U/mL).
| EL.U/mL | Nimenrix + Infanrix-hexa Group | Nimenrix Group | Infanrix-Hexa Group | Meningitec Group |
|---|---|---|---|---|
| Anti-PT [M 0] | 11 (10 to 12) | 10 (8 to 11) | 10 (9 to 12) | 11 (9 to 13) |
| Anti-PT [M 1] | 86 (77 to 95) | 8 (7 to 9) | 85 (75 to 96) | 9 (7 to 10) |
| Anti-PT [M 2] | — | 91 (80 to 102) | 63 (55 to 71) | — |
| Anti-FHA [M 0] | 51 (44 to 59) | 55 (46 to 66) | 49 (41 to 57) | 55 (44 to 68) |
| Anti-FHA [M 1] | 542 (492 to 597) | 48 (40 to 58) | 544 (485 to 611) | 55 (42 to 71) |
| Anti-FHA [M 2] | — | 664 (664 to 750) | 413 (366 to 465) | — |
| Anti-PRN [M 0] | 26 (23 to 31) | 26 (22 to 31) | 21 (17 to 24) | 23 (18 to 28) |
| Anti-PRN [M 1] | 470 (411 to 537) | 23 (19 to 27) | 450 (387 to 522) | 21 (16 to 26) |
| Anti-PRN [M 2] | — | 583 (502 to 676) | 336 (286 to 395) | — |
Solicited local symptoms assessed were pain, redness and swelling. Any was defined as occurrence of any local symptom irrespective of intensity grade. Grade 3 Pain was defined as crying when limb was moved/ spontaneously painful.
| Participants | Nimenrix + Infanrix-hexa Group | Nimenrix Group | Infanrix-Hexa Group | Meningitec Group |
|---|---|---|---|---|
| Any Pain | 49 | 30 | 35 | 16 |
| Grade 3 Pain | 3 | 0 | 1 | 1 |
| Any Redness | 70 | 74 | 56 | 36 |
| Grade 3 Redness | 3 | 8 | 8 | 2 |
| Any Swelling | 42 | 36 | 36 | 23 |
| Grade 3 Swelling | 2 | 3 | 7 | 0 |
The analysis was based only on subjects receiving combined-diphtheria vaccination.
| Participants | Nimenrix + Infanrix-hexa Group | Nimenrix Group | Infanrix-Hexa Group |
|---|---|---|---|
| Any Pain | 60 | 65 | 64 |
| Grade 3 Pain | 6 | 5 | 10 |
| Any Redness | 70 | 77 | 99 |
| Grade 3 Redness | 11 | 14 | 27 |
| Any Swelling | 48 | 53 | 74 |
| Grade 3 Swelling | 12 | 14 | 22 |
Solicited general symptoms assessed were drowsiness, fever, irritability and loss of appetite. Any was defined as occurrence of any general symptom irrespective of intensity grade and relationship. Subjects in the Nimenrix + Infanrix-hexa Group did not receive a second dose of vaccination.
| Participants | Nimenrix + Infanrix-hexa Group | Nimenrix Group | Infanrix-Hexa Group | Meningitec Group |
|---|---|---|---|---|
| Drowsiness, D1 | 85 | 56 | 80 | 29 |
| Fever, D1 | 80 | 41 | 71 | 15 |
| Irritability, D1 | 83 | 63 | 75 | 25 |
| Loss of appetite, D1 | 51 | 46 | 51 | 15 |
| Drowsiness, D2 | 0 | 63 | 56 | 0 |
| Fever, D2 | 0 | 60 | 37 | 0 |
| Irritability, D2 | 0 | 75 | 50 | 0 |
| Loss of appetite, D2 | 0 | 54 | 38 | 0 |
Any was defined as occurrence of at least one symptom experienced.
| Participants | Nimenrix + Infanrix-hexa Group | Nimenrix Group | Infanrix-Hexa Group | Meningitec Group |
|---|---|---|---|---|
| Number of Subjects Reporting Any Rash | 13 | 25 | 22 | 12 |
Any was defined as occurrence of at least one symptom experienced.
| Participants | Nimenrix + Infanrix-hexa Group | Nimenrix Group | Infanrix-Hexa Group | Meningitec Group |
|---|---|---|---|---|
| Number of Subjects Reporting Any New Onset of Chronic Illnesses (NOCIs) | 1 | 2 | 6 | 1 |
Any was defined as occurrence of at least one symptom experienced.
| Participants | Nimenrix + Infanrix-hexa Group | Nimenrix Group | Infanrix-Hexa Group | Meningitec Group |
|---|---|---|---|---|
| Number of Subjects Reporting Any Conditions Prompting Emergency Room Visits (ER) | 5 | 3 | 14 | 6 |
An AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. "Any" was defined as an incidence of an unsolicited AE regardless of intensity or relationship to study vaccination.
| Participants | Nimenrix + Infanrix-hexa Group | Nimenrix Group | Infanrix-Hexa Group | Meningitec Group |
|---|---|---|---|---|
| Number of Subjects Reporting Any Unsolicited Adverse Events (AEs) After the First Dose | 71 | 81 | 83 | 42 |
An AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. "Any" was defined as an incidence of an unsolicited AE regardless of intensity or relationship to study vaccination. The analysis was based only on subjects receiving a second dose of vaccination.
| Participants | Nimenrix Group | Infanrix-Hexa Group |
|---|---|---|
| Number of Subjects Reporting Any Unsolicited Adverse Events (AEs) After the Second Dose | 87 | 79 |
Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/ incapacity.
| Participants | Nimenrix + Infanrix-hexa Group | Nimenrix Group | Infanrix-Hexa Group | Meningitec Group |
|---|---|---|---|---|
| Number of Subjects Reporting Any Serious Adverse Events (SAEs) | 10 | 8 | 11 | 6 |
Collected over SAEs were reported throughout the entire study period (Day 0 - Month 7). Solicited symptoms were reported during a 4-day period (Day 0-Day 3) after any vaccine dose, while unsolicited AEs were collected within 31 days (Days 0-30) after vaccination.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Nimenrix + Infanrix-hexa Group | 0/222 (0%) | 10/222 (4.5%) | 166/222 (74.8%) |
| Nimenrix Group | 0/220 (0%) | 8/220 (3.6%) | 183/220 (83.2%) |
| Infanrix-Hexa Group | 1/224 (0.4%) | 11/224 (4.9%) | 185/224 (82.6%) |
| Meningitec Group | 0/127 (0%) | 6/127 (4.7%) | 75/127 (59.1%) |
| Event | Nimenrix + Infanrix-hexa Group | Nimenrix Group | Infanrix-Hexa Group | Meningitec Group |
|---|---|---|---|---|
| BronchitisInfections and infestations | 1/222 | 0/220 | 0/224 | 2/127 |
| Febrile convulsionNervous system disorders | 2/222 | 0/220 | 1/224 | 0/127 |
| GastroenteritisInfections and infestations | 1/222 | 1/220 | 2/224 | 0/127 |
| Gastroenteritis rotavirusInfections and infestations | 1/222 | 1/220 | 2/224 | 0/127 |
| HypersensitivityImmune system disorders | 0/222 | 0/220 | 0/224 | 1/127 |
| BronchospasmRespiratory, thoracic and mediastinal disorders | 0/222 | 0/220 | 1/224 | 1/127 |
| AnaemiaBlood and lymphatic system disorders | 0/222 | 1/220 | 0/224 | 1/127 |
| Iron deficiencyMetabolism and nutrition disorders | 0/222 | 0/220 | 0/224 | 1/127 |
| Gastroenteritis norovirusInfections and infestations | 1/222 | 0/220 | 1/224 | 1/127 |
| Otitis mediaInfections and infestations | 0/222 | 0/220 | 1/224 | 1/127 |
| Event | Nimenrix + Infanrix-hexa Group | Nimenrix Group | Infanrix-Hexa Group | Meningitec Group |
|---|---|---|---|---|
| ErythemaSkin and subcutaneous tissue disorders | 91/222 | 102/220 | 103/224 | 36/127 |
| IrritabilityPsychiatric disorders | 83/222 | 100/220 | 93/224 | 25/127 |
| SomnolenceNervous system disorders | 85/222 | 89/220 | 95/224 | 29/127 |
| PyrexiaGeneral disorders | 83/222 | 90/220 | 89/224 | 17/127 |
| SwellingGeneral disorders | 64/222 | 66/220 | 85/224 | 23/127 |
| Decreased appetiteMetabolism and nutrition disorders | 51/222 | 78/220 | 68/224 | 15/127 |
| PainGeneral disorders | 68/222 | 75/220 | 69/224 | 16/127 |
| Upper respiratory tract infectionInfections and infestations | 12/222 | 27/220 | 24/224 | 8/127 |
| GastroenteritisInfections and infestations | 6/222 | 18/220 | 18/224 | 4/127 |
| BronchitisInfections and infestations | 7/222 | 16/220 | 12/224 | 6/127 |
| Age, Continuous(Months) | Nimenrix + Infanrix-hexa Group | Nimenrix Group | Infanrix-Hexa Group | Meningitec Group | Total |
|---|---|---|---|---|---|
| Mean | 14.6 ± 3.01 | 15 ± 3.33 | 14.9 ± 3.17 | 14.6 ± 2.99 | 14.8 ± 3.14 |
| Sex/Gender, Customized(Participants) | Nimenrix + Infanrix-hexa Group | Nimenrix Group | Infanrix-Hexa Group | Meningitec Group | Total |
|---|---|---|---|---|---|
| Female | 109 | 106 | 119 | 61 | 395 |
| Male | 113 | 114 | 105 | 66 | 398 |
| Race/Ethnicity, Customized(Participants) | Nimenrix + Infanrix-hexa Group | Nimenrix Group | Infanrix-Hexa Group | Meningitec Group | Total |
|---|---|---|---|---|---|
| White - Caucasian/ European heritage, n (%) | 204 | 205 | 212 | 120 | 741 |
| African heritage / African American | 3 | 4 | 1 | 2 | 10 |
| American Indian or Alaskan native | 2 | 1 | 0 | 1 | 4 |
| Asian - Central/ South Asian heritage | 1 | 2 | 1 | 0 | 4 |
| Asian - East Asian heritage | 2 | 0 | 0 | 0 | 2 |
| Asian - South east Asian heritage | 2 | 0 | 4 | 2 | 8 |
| White - Arabic / North African heritage | 4 | 7 | 4 | 2 | 17 |
| Other | 4 | 1 | 2 | 0 | 7 |
Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.
The record gives a start of Aug 2007, a primary completion of May 2008 and a completion of Oct 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2019, 10 years 7 months after primary completion. A results delay was requested in Sep 2009.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine